Body Composition Stack
The Body Composition Stack groups three peptides studied within growth-hormone-axis and metabolic research.
Why these compounds are studied together
Two of the three components belong to peptide classes with a well-documented research relationship. CJC-1295 is a growth-hormone-releasing hormone (GHRH) analog and Ipamorelin is a growth-hormone secretagogue of the GHRP class — and in published research, GHRH peptides and GHRP peptides have been shown to act synergistically on growth-hormone secretion, with combinations producing a substantially greater increase in pulsatile GH release than either class administered alone. AOD-9604, a modified fragment of growth hormone (hGH 176–191), is studied separately within lipid-metabolism research. Together, the stack reflects two established themes in growth-hormone-axis research — secretagogue-driven GH release and growth-hormone-fragment metabolic research.
Individual research backgrounds
AOD-9604
AOD-9604 (also designated Tyr-hGH177-191) is a synthetic 16-amino-acid peptide consisting of the C-terminal hGH177-191 fragment of human growth hormone (a 15-residue sequence) with an additional N-terminal tyrosine residue added for stabilization and cyclized through a disulfide bond between its two cysteine residues.
AOD-9604 has been the subject of pre-clinical investigations using in vitro models, rodent models of obesity (including ob/ob mice and beta-3 adrenergic receptor knock-out mice), and non-human primate chronic-toxicology studies in cynomolgus monkeys. In vitro genotoxicology assays documented in the peer-reviewed literature include the Ames test, a chromosomal aberration assay, and a micronucleus assay, in which the compound was reported as non-mutagenic, non-clastogenic, and not inducing a consistent increase in micronuclei. Separately, a 2022 study published in Drug Design, Development and Therapy examined the human growth hormone 176-191 fragment in MCF-7 breast cancer cell cultures alongside molecular docking simulations targeting the estrogen receptor, HER2, and related biomarkers; that study addresses a differently-numbered fragment (176-191) and does not establish it as the same molecule as AOD-9604.
Ipamorelin
Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide classified as a selective growth hormone secretagogue that acts at the growth hormone secretagogue (GHRP) receptor.
Ipamorelin has been investigated in primary rat pituitary cell cultures (in vitro) and in vivo rodent and swine models, where its pharmacological selectivity profile was characterized against other growth hormone-releasing peptides (GHRPs) including GHRP-6 and GHRP-2. Chronic in vivo administration studies in young female Wistar rats examined its effects on somatotroph cell populations and pituitary responsiveness over 21-day treatment periods. Additional rodent studies have evaluated its activity in models of postoperative gastrointestinal dysmotility, and dose-response studies in adult female Sprague-Dawley rats assessed longitudinal bone growth rate and systemic growth factor parameters.
CJC-1295
CJC-1295 with DAC is a synthetic, tetra-substituted growth hormone-releasing hormone (GHRH) analogue based on the GHRH-(1-29)NH2 sequence and modified with a Drug Affinity Complex (DAC) moiety that binds endogenous serum albumin, extending the peptide's circulating half-life relative to native GHRH.
CJC-1295 has been examined in several research models. A review of chemical modifications of Class II G-protein-coupled receptor ligands notes that the compound has been tested in several animal species, including dogs and pigs, as well as in humans. In a rodent model, GHRH-knockout (GHRHKO) mice were administered CJC-1295 at intervals of 24, 48, and 72 hours over a five-week period to assess growth normalization in the setting of GHRH deficiency; in that study, animals receiving daily doses exhibited normal body weight and length, with normal relative lean mass and subcutaneous fat mass reported across the treated groups. A separate gerontology review characterizing the compound notes that it was not approved and that Phase 2 development was discontinued.
This stack is sold strictly for in-vitro and laboratory research purposes only.